Loading…
Pulsenmore Ltd.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in PLSM.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| HKPDCellyan Biotechnology Co., Ltd | $0.35 | — | 0.9x | — | -15.59% | $16.84M |
| CTXRCitius Pharmaceuticals, Inc. | $0.60 | — | 0.2x | — | -81.09% | $16.53M |
| PLURPluri Inc. | $1.53 | — | — | — | — | $16.51M |
| ADILAdial Pharmaceuticals Inc | $5.60 |
Pulsenmore Ltd., a medical device company, engages in the research, development, manufacture, marketing, and sale of portable ultrasound solutions. The company provides Pulsenmore ES and Pulsenmore FC products. The company was incorporated in 2014 and is based in Omer, Israel.
Company description provided by Yahoo Finance.
| — |
| — |
| — |
| -2011.64% |
| $16.43M |
| LEXXLexaria Bioscience Corp. | $10.35 | — | 3.6x | — | -162.77% | $17.1M |
| MDCXMedicus Pharma Ltd. | $0.26 | — | — | — | -7446.11% | $16.28M |